Biotech Will Recover!

G. Steven Burrill;

Publication

Article

October 15, 2002

BioPharm International

BioPharm International-10-01-2002

Volume15

Issue 10

Biotech Will Recover!

Author(s):

G. Steven Burrill

by G. Steven Burrill, Burrill & Company Beleagured by bad news since the start of the year, biotech is barely registering a pulse on Wall Street . . . but it's hardly time to write the industry's obituary.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

FDA Launches Major CGMP Review

Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)

Process Validation: How Much to Do and When to Do It

Biotech Will Recover!

Preparing Biological Product Deviation Reports: Suggestions for Manufacturers

GMPs and Pharmaceutical Labeling

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!